NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
19 Nov 2015

CVRx® Announces Expedited Access Pathway Designation by FDA for Barostim Therapy® for the Treatment of Heart Failure in Order to Accelerate Access for US Patients

Minneapolis – November 19, 2015 – CVRx, Inc., a private medical device company, announced that it received Expedited Access Pathway (EAP) Designation by FDA for Barostim Therapy® for the treatment of heart failure.
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)<
14 Oct 2015

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

Funds will help company reach clinical validation for lead candidate in X-ALD, a rare neurodegenerative and life-threatening disease
30 Sep 2015

AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury

Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces the publication of two papers on recAP for the potential treatment of Acute Kidney Injury (AKI).
29 Sep 2015

AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

Bunnik, The Netherlands, 29 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the global pharmaceutical industry.
IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone<
16 Sep 2015

IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone

This new knowledge may accelerate the development of the first preventive treatment of bone metastasis 
15 Sep 2015

TiGenix Business and Financial Update for the First Half of 2015

Leuven (BELGIUM) - 15 September 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced its Business and Financial Update for the first half of 2015 and recent significant events.
10 Sep 2015

NITID (optical coherence tomography and digital dermatoscope handheld device) – CE Mark approval received

Madrid, September 10, 2015. DermaLumics, a recently founded spin-off of optical tomography systems developer MedLumics, announces that NITID, its first skin diagnostic solution, received CE Mark approval in Europe.
Sanifit raises €36.6M ($41.3M) in Series C financing round<
08 Sep 2015

Sanifit raises €36.6M ($41.3M) in Series C financing round

The investment was led by Ysios Capital and supported by a substantial syndicate of new investors.
24 Aug 2015

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial

A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 24 of complex perianal fistulas in Crohn's disease patients with inadequate response to previous therapies, including anti-TNFs
30 Jul 2015

TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition

Leuven (BELGIUM) – July 30, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic adipose-derived stem cells, announced today the acquisition of cardiology-focused cell therapy company Coretherapix S.L., currently owned by Genetrix S.L. Its lead programme, AlloCSC-01, is an allogeneic cardiac stem cell product currently in a Phase II clinical trial in acute myocardial infarction (AMI), with interim data expected in the second half of 2016.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка